The implications of SB1773 are significant for individuals living with various forms of diabetes. By ensuring comprehensive coverage for CGMs, the bill aims to facilitate better management of diabetes for a wider range of patients. This could potentially improve health outcomes by providing patients with necessary tools to monitor their glucose levels more effectively. This expansion aligns with contemporary healthcare models that emphasize proactive management of chronic conditions through technology.
Summary
Senate Bill 1773, introduced by Senator Julie A. Morrison, seeks to amend the Illinois Insurance Code by expanding coverage mandates for continuous glucose monitors (CGMs) within health insurance policies. The bill stipulates that starting January 1, 2024, both group and individual health insurance policies, as well as managed care plans, must cover medically necessary CGMs for a broader set of diabetes diagnoses. This includes not only type 1 and type 2 diabetes but also gestational diabetes, maturity-onset diabetes of the young, neonatal diabetes, and various other specific types leading to insulin requirement for diabetes management.
Contention
Debate surrounding the bill may emerge from differing perspectives on healthcare funding and the costs associated with mandating additional coverage. Proponents argue that the benefits of better diabetes management and the long-term reduction in healthcare costs justify the inclusion of broader coverage provisions. However, opponents may raise concerns regarding the implications for insurance premiums and coverage limits, indicating that such mandates could lead to higher costs for insurers and potentially limit other types of coverage or affordability for consumers.
Requires health insurance plans to provide coverage for continuous blood glucose monitors for all children; requires coverage for glucose monitoring devices for all sugar disorders.
Requires health insurance plans to provide coverage for continuous blood glucose monitors for all children; requires coverage for glucose monitoring devices for all sugar disorders.